Cremophor EL-mediated alteration of paclitaxel distribution in human blood: Clinical pharmacokinetic implications

Cancer Research

Volumn 59, Issue 7, 1999, Pages 1454-1457

  Sparreboom, Alex ^a,b   Van Zuylen, Lia ^a   Brouwer, Eric ^a   Loos, Walter J ^a   De Bruijn, Peter ^a   Gelderblom, Hans ^a   Pillay, Marrimuthoo ^a   Nooter, Kees ^a   Stoter, Gerrit ^a   Verweij, Jaap ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CREMOPHOR; GLYCOPROTEIN P; PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BILE SECRETION; BINDING AFFINITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DISPOSITION; DRUG DISTRIBUTION; HUMAN; HUMAN CELL; MICELLE; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ERYTHROCYTES; FEMALE; GLYCEROL; HUMANS; MICELLES; PACLITAXEL; VEHICLES;

EID: 0033118955     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Kearns, C. M. Pharmacokinetics of the taxanes. Pharmacotherapy, 17: 105S-109S, 1997.
2. Gianni, L., Kearns, C. M., Giani, A., Capri, G., Vigano, L., Locatelli, A., Bonadonna, G., and Egorin, M. J. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J. Clin. Oncol., 13: 180-190, 1995.
3. Sparreboom, A., Van Tellingen, O., Nooijen, W. J., and Beijnen, J. H. Tissue distribution, metabolism and excretion of paclitaxel in mice. Anticancer Drugs, 9: 78-87, 1996.
4. Sparreboom, A., Van Tellingen, O., Nooijen, W. J., and Beijnen, J. H. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res., 56: 2112-2115, 1996.
5. Sparreboom, A., Van Tellingen, O., Nooijen, W. J., and Beijnen, J. H. Preclinical pharmacokinetics of paclitaxel and docetaxel. Anticancer Drugs, 9: 1-17, 1998.
6. Brouwer, E., Verweij, J., Hauns, B., Loos, W. J., Nooter, K., Mross, K., Stoter, G., and Sparreboom. A. Linearized colorimetric assay for Cremophor EL: application to pharmacokinetics after 1-hour paclitaxel infusions. Anal. Biochem., 261: 198-202, 1998.
7. Gianni, L., Vigano, L., Locatelli, A., Capri, G., Giani, A., Tarenzi, E., and Bonadonna, G. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J. Clin. Oncol., 15: 1906-1915, 1997.
8. Sparreboom, A., Van Asperen, J., Mayer, U., Schinkel, A. H., Smit, J. W., Meijer, D. K. F., Borst, P., Nooijen, W. J., Beijnen, J. H., and Van Tellingen, O. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. USA. 94: 2031-2035, 1997.
9. Schinkel, A. H., Mayer, U., Wagenaar, E., Mol, C. A., Van Deemter, L., Smit, J. J., Van der Valk, M. A., Voordouw, A. C., Spits, H., Van Tellingen, O., Zijlmans, J. M., Fibbe, W. E., and Borst, P. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc. Natl. Acad. Sci. USA, 94: 4028-4033, 1997.
10. Sparreboom, A., Verweij, J., Van der Burg, M. E. L., Loos, W. J., Brouwer, E., Vigano, L., Locatelli, A., De Vos, A. I., Nooter, K., Stoter, G., and Gianni, L. Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. Clin. Cancer Res., 4: 1937-1942, 1998.
11. Kessel, D., Woodburn, K., Decker, D., and Sykes, E. Fractionation of Cremophor EL delineates components responsible for plasma lipoprotein alterations and multidrug resistance reversal. Oncol. Res., 7: 207-212, 1995.
12. Sparreboom, A., De Bruijn, P., Nooter, K., Loos, W. J., Stoter, G., and Verweij, J. Determination of paclitaxel in human plasma using single solvent extraction prior to isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection. J. Chromatogr., 705: 159-164, 1998.
13. Sparreboom, A., Loos, W. J., Verweij, J., De Vos, A. I., Van der Burg, M. E. L., Stoter, G., and Nooter, K. Quantitation of Cremophor EL in human plasma samples using a colorimelric dye-binding microassay. Anal. Biochem., 255: 171-175, 1998.
14. Highley, M. S., and De Bruijn, E. A. Erythrocytes and the transport of drugs and endogenous compounds. Pharmaceut. Res. (N Y), 13: 186-195, 1996.
15. 1-acid glycoprotein. Res. Commun. Chem. Pathol. Pharmacol., 80: 337-342, 1993.
16. Wild, M. D., Walle, U. K., and Walle, T. Extensive and saturable accumulation of paclitaxel by the human platelet. Cancer Chemother. Pharmacol., 36: 41-44, 1995.
17. Kessel, D. Properties of Cremophor EL micelles probed by fluorescence. Photochem. Photobiol., 56: 447-451, 1992.
18. Sykes, E., Woodburn, K., Decker, D., and Kessel, D. Effects of Cremophor EL on distribution of Taxol to serum lipoproteins. Br. J. Cancer, 70: 401-404, 1994.
19. Webster, L. K., Cosson, E. J., Stokes, K. H., and Millward, M. J. Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice. Br. J. Cancer. 73: 522-524, 1996.
20. Ellis, A. G., Crinis, N. A., and Webster, L. K. Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. Cancer Chemother. Pharmacol., 38: 81-87, 1996.